← All trials
NCT03037385
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 17, 2017
- Primary completion
- Mar 1, 2021
- Completion date
- Mar 1, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 115
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Blueprint Medicines CorporationLead sponsor
Drugs studied
Indications studied
- Thyroid Cancer, Papillary
- Adenocarcinoma
- Adenocarcinoma, Papillary
- Bronchial Neoplasms
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Non-Small-Cell Lung
- Colonic Diseases
- Colonic Neoplasms
- Digestive System Diseases
- Digestive System Neoplasms
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Head and Neck Neoplasms
- Intestinal Diseases
- Intestinal Neoplasms
- Lung Diseases
- Lung Neoplasms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Glandular and Epithelial
- Neoplasms, Nerve Tissue
- Respiratory Tract Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Thyroid Diseases
- Thyroid Neoplasms
- Colorectal Neoplasms
- Neuroectodermal Tumors
- Carcinoma, Neuroendocrine
- Neuroendocrine Tumors
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.